Drug Profile
Atibuclimab - Implicit Bioscience
Alternative Names: Anti-CD14 antibody; IC-14Latest Information Update: 27 Feb 2024
Price :
$50
*
At a glance
- Originator ICOS Corporation
- Developer ICOS Corporation; Implicit Bioscience; National Institute of Allergy and Infectious Diseases; University of Washington; Vanderbilt University Medical Center
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Monoclonal antibodies
- Mechanism of Action CD14 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acute lung injury; SARS-CoV-2 acute respiratory disease
- No development reported Adult respiratory distress syndrome; Motor neuron disease
- Discontinued Septic shock
Most Recent Events
- 19 Feb 2024 Implicit Bioscience plans a phase I/II trial for Cardiomyopathies in USA (IV) in February 2024(NCT06275893)
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in SARS-COV-2 acute respiratory disease in Italy (IV, Infusion)
- 01 Apr 2022 National Institute of Allergy and Infectious Diseases (NIAID) in collaborations with University of Washington, Implicit Bioscience and Vanderbilt University Medical Center terminates a phase II CaTT trial in SARS-COV-2 acute respiratory disease in USA (IV), due to slow patient enrollment rate (NCT04391309)